



Formula: C₂₇H₃₇FO₆

MW: 476.59

CAS: 2152-44-5

MDL NUMBER: MFCD03225534

IUPAC: (2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0.0]heptadeca-3,6-dien-14-yl pentanoate

Smiles:

C=12[C]([C]3([C@H](C[C]4([C@]([C@@H](C)C[C@@H]4([C@@H]3(CC2))))(C(=O)CO)OC(=O)CCCC)C)O)F)(C=CC(=O)C1)C

Glucocorticoid

THERAPEUTIC CATEGORY: Glucocorticoid

ACCEPTORS: 6

DONORS: 2

ROTATION BONDS: 7

N+O: 6

Chiral Centers: 8

LogP: 5.02

LogS: -5.53

LIPINSKI: 4

Synonyms:

VALISONE;(11-beta,16-beta-l)oxy);17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione-9-fluoro-11-beta;17-valerate;Betamethasonevalerateester;betnovateat;celestoderm;pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl

CAS:2152-44-5

MF:C27H37FO6

MW:476.58

EINECS:218-439-3

Product Categories: Betamethasone 17-valerate

Chemical Properties: storage temp. 2-8C Merck 13,1183

CAS DataBase Reference: 2152-44-5(

CAS DataBase Reference:) EPA Substance Registry SystemPregna-1,4-diene- 3,20-dione, 9-fluoro-11,21-dihydroxy-16- methyl-17-[(1-oxopentyl)oxy]-, (11.beta.,16.beta.)-(2152-44-5) Xn Risk Statements 48 Safety Statements 22-24/25 RIDADR UN 2811 6.1/PG 3 WGK Germany 2 RTECS TU3835000 1,4-Pregnadiene-11b,17a,21-triol-9a-fluoro-16b-methyl-3,20-dione 17-valerate Betamethasone 17-valerate

Usage And Synthesis: Betamethasone 17-valerate

